Inspire Medical Systems, Inc. (NYSE:INSP) Shares Acquired by Xponance Inc.

Xponance Inc. increased its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 2.2% in the 4th quarter, HoldingsChannel reports. The firm owned 3,824 shares of the company’s stock after buying an additional 82 shares during the quarter. Xponance Inc.’s holdings in Inspire Medical Systems were worth $709,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of INSP. First Horizon Advisors Inc. boosted its position in Inspire Medical Systems by 885.7% during the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 124 shares during the last quarter. True Wealth Design LLC purchased a new stake in Inspire Medical Systems in the third quarter valued at approximately $30,000. Harbour Investments Inc. increased its position in Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after purchasing an additional 99 shares during the last quarter. AlphaQuest LLC raised its stake in Inspire Medical Systems by 7,275.0% during the fourth quarter. AlphaQuest LLC now owns 295 shares of the company’s stock worth $55,000 after purchasing an additional 291 shares during the period. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Inspire Medical Systems by 178.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock valued at $66,000 after purchasing an additional 229 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Insider Buying and Selling at Inspire Medical Systems

In related news, CTO John Rondoni sold 583 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares of the company’s stock, valued at $1,777,187.76. This represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Randy Ban sold 25,584 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,225 shares of company stock valued at $4,806,530 in the last three months. Corporate insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on INSP shares. Piper Sandler dropped their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Royal Bank of Canada restated an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, February 11th. Truist Financial reduced their price objective on Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a research report on Tuesday, February 11th. Finally, Stifel Nicolaus reduced their price target on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $228.82.

Inspire Medical Systems Trading Up 3.6 %

INSP opened at $170.89 on Tuesday. Inspire Medical Systems, Inc. has a twelve month low of $123.00 and a twelve month high of $257.40. The firm has a market cap of $5.09 billion, a price-to-earnings ratio of 98.78, a PEG ratio of 2.86 and a beta of 1.48. The company has a fifty day simple moving average of $180.18 and a 200 day simple moving average of $191.19.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.